Xtandi 40 MG capsule 120S
Ended Awarded Last action
- Contract number
- SPE2DR26FRBV9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $17,021
Award facts
- Contract value 100% obligated
- $17,021.36 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $17,021.36 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). This firm fixed-price delivery order, awarded on December 10, 2025, with an ultimate completion date of December 11, 2025, carries no set-aside designation, indicating the award was made on a competitive basis. The order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition vehicle designed to streamline pharmaceutical procurement for Department of Defense medical facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, demonstrating consistent performance across multiple therapeutic categories. The company's IDC, designated SPE2DR and awarded November 13, 2025, carries a ceiling value of $499,999,999 with a completion date of December 31, 2036, structured as a 30-month base period with three 30-month option periods. As one of multiple regional prime vendor contractors under PPV-G GEN V, DMS Pharmaceutical Group is authorized to supply branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables to support Department of Defense healthcare operations globally, with this particular delivery order reflecting the company's capability to fulfill specialized pharmaceutical requirements for military medical systems.
Quick answers
Who was awarded contract SPE2DR26FRBV9?
SPE2DR26FRBV9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 10, 2025.
How much is contract SPE2DR26FRBV9 worth?
The government has obligated $17,021 on SPE2DR26FRBV9.
Is contract SPE2DR26FRBV9 an order under another contract?
Yes. SPE2DR26FRBV9 is a delivery order under SPE2DR25D9206, an indefinite delivery contract.
Was contract SPE2DR26FRBV9 competed?
The extent of competition for SPE2DR26FRBV9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award